JP2021531268A5 - - Google Patents

Info

Publication number
JP2021531268A5
JP2021531268A5 JP2021500915A JP2021500915A JP2021531268A5 JP 2021531268 A5 JP2021531268 A5 JP 2021531268A5 JP 2021500915 A JP2021500915 A JP 2021500915A JP 2021500915 A JP2021500915 A JP 2021500915A JP 2021531268 A5 JP2021531268 A5 JP 2021531268A5
Authority
JP
Japan
Prior art keywords
domain
polypeptide
monomer
igg1
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021500915A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021531268A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/041406 external-priority patent/WO2020014486A1/en
Publication of JP2021531268A publication Critical patent/JP2021531268A/ja
Publication of JP2021531268A5 publication Critical patent/JP2021531268A5/ja
Withdrawn legal-status Critical Current

Links

JP2021500915A 2018-07-11 2019-07-11 改変されたＦｃ抗原結合ドメイン構築体に関する組成物および方法 Withdrawn JP2021531268A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862696618P 2018-07-11 2018-07-11
US62/696,618 2018-07-11
PCT/US2019/041406 WO2020014486A1 (en) 2018-07-11 2019-07-11 Compositions and methods related to engineered fc-antigen binding domain constructs

Publications (2)

Publication Number Publication Date
JP2021531268A JP2021531268A (ja) 2021-11-18
JP2021531268A5 true JP2021531268A5 (enExample) 2022-07-14

Family

ID=69142016

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021500915A Withdrawn JP2021531268A (ja) 2018-07-11 2019-07-11 改変されたＦｃ抗原結合ドメイン構築体に関する組成物および方法

Country Status (11)

Country Link
US (1) US20220267460A1 (enExample)
EP (1) EP3820519A4 (enExample)
JP (1) JP2021531268A (enExample)
KR (1) KR20210042326A (enExample)
CN (1) CN113164591A (enExample)
AU (1) AU2019302740A1 (enExample)
BR (1) BR112021000392A2 (enExample)
CA (1) CA3106212A1 (enExample)
IL (1) IL279998A (enExample)
MX (1) MX2021000287A (enExample)
WO (1) WO2020014486A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102050463B1 (ko) 2016-08-10 2019-11-29 아주대학교산학협력단 항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 사이토카인 (heterodimeric Fc-fused cytokine) 및 이를 포함하는 약제학적 조성물
EP3658172A4 (en) 2017-07-25 2021-05-05 TrueBinding, Inc. TREATING CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND HIS LIGAND
CA3117212A1 (en) * 2018-10-23 2020-04-30 Dragonfly Therapeutics, Inc. Heterodimeric fc-fused proteins
CN113711036B (zh) 2019-01-30 2025-03-18 真和制药有限公司 抗gal3抗体及其用途
CN116157151A (zh) 2020-05-26 2023-05-23 真和制药有限公司 通过阻断半乳凝素-3治疗炎性疾病的方法
WO2023079147A1 (en) * 2021-11-05 2023-05-11 Oslo Universitetssykehus Hf Iga fc and igg fc tandem protein constructs

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080311034A1 (en) * 2007-04-30 2008-12-18 Anderson Glenn M Anti-Tissue Factor Antibodies and Compositions with Enhanced Effector Function
CN103897063B (zh) * 2007-06-01 2017-04-12 马里兰大学巴尔的摩分校 免疫球蛋白恒定区Fc受体结合剂
CN103857700A (zh) * 2011-08-26 2014-06-11 梅里麦克制药股份有限公司 串联fc双特异性抗体
KR20150058236A (ko) * 2012-08-20 2015-05-28 글리크닉 인코포레이티드 항원 결합 및 다가 fc 감마 수용체 결합 활성을 가진 분자
UA117289C2 (uk) * 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
SG10201913507SA (en) * 2014-05-02 2020-02-27 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc constructs
CA3025310A1 (en) * 2016-05-23 2017-11-30 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc constructs
AU2018205272A1 (en) * 2017-01-06 2019-07-25 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered Fc-antigen binding domain constructs

Similar Documents

Publication Publication Date Title
IL261674A (en) Protein-like binding proteins with a double variable region have a cross-linking region direction
JP2020531438A5 (ja) Ｎｋｇ２ｄ、ｃｄ１６、およびｈｌａ−ｅに結合するタンパク質
RU2019124709A (ru) КОМПОЗИЦИИ И СПОСОБЫ, СВЯЗАННЫЕ СО СКОНСТРУИРОВАННЫМИ КОНСТРУКЦИЯМИ НА ОСНОВЕ Fc-АНТИГЕНСВЯЗЫВАЮЩЕГО ДОМЕНА
JP2019534277A5 (enExample)
Carter Bispecific human IgG by design
JP2022551969A5 (enExample)
JP2018046872A5 (enExample)
FI3392276T3 (fi) Heterodimeerimolekyyli, joka perustuu rakenteelliseen CH3-domeeniin, sekä menetelmä sen valmistamiseksi ja sen käyttö
JP2018537966A5 (enExample)
IL299221A (en) Cd3 binding antibodies
FI3749346T3 (fi) Nkg2d-reseptoriin kohdistuvat vasta-aineen vaihtelevan domeenin yhdistelmät
HRP20211528T1 (hr) Trispecifični i/ili trovalentni vezujući proteini za prevenciju ili liječenje hiv infekcije
JP2021533159A5 (enExample)
JP2022504802A5 (enExample)
JP2020514301A5 (enExample)
JP2023538945A5 (enExample)
RU2021110369A (ru) Белки, связывающие nkg2d, cd16 и опухолеассоциированный антиген
JP2018527903A5 (enExample)
JP2018522541A5 (enExample)
HRP20150444T1 (hr) Trovalentna, bispecifiäśna protutijela
RU2011148913A (ru) Иммуноглобулин с двумя вариабельными доменами и его применение
HRP20201004T1 (hr) Modificirani polipeptidi za skelete bispecifičnog protutijela
JP2017504578A5 (enExample)
RU2019129511A (ru) Белки, связывающие gd2, nkg2d и cd16
JP2021520832A5 (enExample)